Distinguished in Generalized Resistance to Thyroid Hormone

Patrice Rodien

4, Rue Larrey, 
Angers, FR 
Distinguished in Generalized Resistance to Thyroid Hormone
4, Rue Larrey, 
Angers, FR 
OverviewLocationsClinical Research

Overview

Patrice Rodien practices in Angers, France. Ms. Rodien is rated as a Distinguished expert by MediFind in the treatment of Generalized Resistance to Thyroid Hormone. Her top areas of expertise are Generalized Resistance to Thyroid Hormone, Familial Hyperthyroidism due to Mutations in TSH Receptor, Hypothyroidism, Thyroidectomy, and Parathyroidectomy.

Her clinical research consists of co-authoring 78 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 8 articles in the study of Generalized Resistance to Thyroid Hormone.

Gender
Female

Locations

4, Rue Larrey, Angers, 49100, France
Other Locations
France
La Tronche, 38700, France
Lille, 59000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological
Study Drug: rhPTH(1-84)
Study Phase: Phase 4
A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Enrollment Status: Completed
Publish Date: August 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

78 Total Publications

NATURAL HISTORY OF MEDULLARY THYROID CARCINOMA IN MEN-2 PATIENTS CARRYING A VARIANT AT CODON 804 IN THE RET PROTO-ONCOGENE: A STUDY BY THE FRENCH NEUROENDOCRINE TUMOR GROUP (GTE).
NATURAL HISTORY OF MEDULLARY THYROID CARCINOMA IN MEN-2 PATIENTS CARRYING A VARIANT AT CODON 804 IN THE RET PROTO-ONCOGENE: A STUDY BY THE FRENCH NEUROENDOCRINE TUMOR GROUP (GTE).
Journal: Annales d'endocrinologie
Published: September 06, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Rodien's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 32 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile